Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M G Lebwohl

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
The Journal of Investigative Dermatology|November 9, 2000
Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2R Fleischmajer, K Kuroda, R Hazan, et al.
The British Journal of Dermatology|March 1, 2018
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3K A Papp, K B Gordon, R G Langley, et al.
Photochemistry and Photobiology|November 24, 1999
p53 mutations in basal cell carcinomas arising in routine users of sunscreensB S Rosenstein, R G Phelps, M A Weinstock, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 18, 2015
Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis surveyP C M van de Kerkhof, K Reich, A Kavanaugh, et al.
The British Journal of Dermatology|June 22, 2021
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-upK A Papp, M G Lebwohl, L Puig, et al.
Journal of the American Academy of Dermatology|May 1, 1986
Importance of complete cutaneous examination for the detection of malignant melanomaD S Rigel, R J Friedman, A W Kopf, et al.
The Journal of Experimental Medicine|September 7, 2000
Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cellsJ R Abrams, S L Kelley, E Hayes, et al.
The British Journal of Dermatology|June 21, 2019
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeksK Reich, R B Warren, L Iversen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 23, 2022
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2A P Fernandez, E Dauden, S Gerdes, et al.
Journal of the American Academy of Dermatology|October 20, 1998
Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasisM G Lebwohl, D L Breneman, B S Goffe, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
The Journal of Investigative Dermatology|November 9, 2000
Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2R Fleischmajer, K Kuroda, R Hazan, et al.
The British Journal of Dermatology|March 1, 2018
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3K A Papp, K B Gordon, R G Langley, et al.
Photochemistry and Photobiology|November 24, 1999
p53 mutations in basal cell carcinomas arising in routine users of sunscreensB S Rosenstein, R G Phelps, M A Weinstock, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 18, 2015
Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis surveyP C M van de Kerkhof, K Reich, A Kavanaugh, et al.
The British Journal of Dermatology|June 22, 2021
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-upK A Papp, M G Lebwohl, L Puig, et al.
Journal of the American Academy of Dermatology|May 1, 1986
Importance of complete cutaneous examination for the detection of malignant melanomaD S Rigel, R J Friedman, A W Kopf, et al.
The Journal of Experimental Medicine|September 7, 2000
Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cellsJ R Abrams, S L Kelley, E Hayes, et al.
The British Journal of Dermatology|June 21, 2019
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeksK Reich, R B Warren, L Iversen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 23, 2022
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2A P Fernandez, E Dauden, S Gerdes, et al.
Journal of the American Academy of Dermatology|October 20, 1998
Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasisM G Lebwohl, D L Breneman, B S Goffe, et al.
Pageof 4